Primary outcomes: safety and tolerability
To evaluate safety, we examined changes in vital signs, electrocardiograms (ECGs), clinical laboratory tests and suicidality from baseline (day −1) to day 1 (Table Safety and tolerability: treatment-emergent AEs and summary of safety measures at post-treatment (day 1)COMP360, psilocybin.